Pharmacological Effects of Aesculus Extracts in Oncology and Vascular Health

Aesculus extracts, most notably those derived from horse chestnut seeds and bark, are rich in triterpenoid saponins (principally escin), flavan-3-ols and coumarins. In vascular medicine, these preparations exert venotonic, anti-edematous and anti-inflammatory effects by modulating endothelial permeability, stabilising capillary walls and inhibiting pro-inflammatory mediators. In oncology, escin and related saponins have demonstrated multi-faceted anti-tumour activities, including induction of apoptosis, suppression of metastasis via inhibition of epithelial-mesenchymal transition and blockade of angiogenesis. These compounds also interact with the tumour microenvironment, reducing extracellular matrix deposition and impairing stromal support for cancer cell dissemination. Mechanistic studies point to modulation of signalling pathways such as NF-κB, HIF-1α and bradykinin, as well as direct scavenging of reactive oxygen and nitrogen species. Taken together, the dual profile of vascular protection and anti-cancer potential positions Aesculus extracts as promising candidates for adjuvant therapy in chronic venous disorders and malignancy management.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Effects of Aesculus Extracts in Oncology and Vascular Health publication trend

The graph below shows the total number of articles in pharmacological effects of aesculus extracts in oncology and vascular health across all publications each year (not limited to Nature Index journals).

Technical terms

Escin: A mixture of triterpenoid saponins extracted from Aesculus seeds, responsible for anti-edematous, venotonic and anti-tumour activities.

Triterpenoid saponin: Amphiphilic plant secondary metabolites composed of a triterpene aglycone linked to sugar moieties, noted for membrane-modulating and immunomodulatory effects.

Bradykinin pathway: A biochemical cascade generating the pro-inflammatory peptide bradykinin, which increases vascular permeability and contributes to oedema formation.

Angiogenesis: The process of new blood vessel formation from existing vasculature, critical for tumour growth and metastasis and a key target for anti-cancer therapy.

Tumour microenvironment: The complex milieu of stromal cells, extracellular matrix and signalling molecules that supports cancer cell survival, proliferation and dissemination.

References

1. Escin’s Action on Bradykinin Pathway: Advantageous Clinical Properties for an Unknown Mechanism?. Antioxidants (2024).
2. Escin’s Multifaceted Therapeutic Profile in Treatment and Post-Treatment of Various Cancers: A Comprehensive Review. Biomolecules (2023).
3. Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor‐kappaB Signaling Pathway. Biochemistry Research International (2013).
4. Bioactive Triterpenoid Saponins From the Seeds of Aesculus chinensis Bge. var. chekiangensis. Frontiers in Chemistry (2020).
5. β-Escin Effectively Modulates HUVECs Proliferation and Tube Formation. Molecules (2018).
6. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression. Oncotarget (2016).
7. Potential Activity Mechanisms of Aesculus hippocastanum Bark: Antioxidant Effects in Chemical and Biological In Vitro Models. Antioxidants (2021).
8. The Natural Product β-Escin Targets Cancer and Stromal Cells of the Tumor Microenvironment to Inhibit Ovarian Cancer Metastasis. Cancers (2021).